Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioverativ Inc.

www.bioverativ.com

Latest From Moebius Medical Ltd.

Deal Watch: Focus Placed On Psoriasis With Recent Purdue, Sienna Deals

Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Alias(es)
  • Biogen Idec Hemophilia Inc.
  • Syntonix Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Bioverativ Inc.
  • Senior Management
  • John G Cox, CEO
    John Greene, EVP, CFO
    Tim Harris, PhD, DSc, EVP, R&D
    Richard Brudnick, EVP, Bus. Dev. & Alliance Management
  • Contact Info
  • Bioverativ Inc.
    Phone: (781) 663-4400
    225 Second Ave.
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register